Evidence used
- CISA confirms exploitation in the wild.
- EPSS is 54.06% for the current model date.
BlackTreeCVE IntelligenceMicrosoft · Exchange Server
CISA confirms exploitation in the wild and lists 2024-09-11 as the remediation due date.
CISA confirms exploitation in the wild and lists 2024-09-11 as the remediation due date.
Patch availableMicrosoft Exchange Server contains an information disclosure vulnerability that allows for remote code execution.
Microsoft Exchange Server contains an information disclosure vulnerability that allows for remote code execution.
The current structured CVE record identifies a security weakness, but the root cause requires confirmation in the linked vendor material.
An attacker operating through a network path may attempt exploitation with elevated privileges. If successful, the issue may execute code or commands in the affected security context.
Microsoft Exchange Server contains an information disclosure vulnerability that allows for remote code execution.
The current structured CVE record identifies a security weakness, but the root cause requires confirmation in the linked vendor material.
An attacker operating through a network path may attempt exploitation with elevated privileges. If successful, the issue may execute code or commands in the affected security context.
CVSS severity, EPSS forecast probability, public exploit material and CISA-confirmed exploitation are separate signals.
CISA added this CVE to its Known Exploited Vulnerabilities catalogue on 2024-08-21.
No exploit-tagged reference or CISA SSVC proof-of-concept state is currently recorded. Research may still exist outside the structured feeds.
CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:H/I:H/A:H/E:U/RL:O/RC:CCommon Vulnerability Scoring System 3.1: the compact vector below is decoded into plain language.
Operational remediation based on structured source evidence.
Published 14 Jul 2021 · Last source change 10 Aug 2026, 15:10 UTC · CWE not yet assigned
Missing structured fields: CWE classification. Missing data is not evidence of low risk; review the primary advisory.